Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharmâ€), a leading European specialty pharmaceutical company...

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Haleon today announces the appointment of Carl Haney as...

API China 2025 Concludes with Strong Turnout and Industry-Wide Momentum

Asia’s leading pharma show draws 200,000 visits and nearly...

Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, and Quotient Sciences, a drug development and manufacturing accelerator, announced an update on the development of Oxilio’s OXL001 product.

Oxilio is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its first Clinical Trial Application (CTA) with OXL001.

Following initial formulation development by Oxilio in collaboration with its partner company, TRx Biosciences, Quotient Sciences’ integrated Translational Pharmaceutics® platform has been used to carry out the technical transfer and scale-up activities associated with this program and will continue to be used to support clinical trial material manufacturing and the investigation of the pharmacokinetics and safety of OXL001 in healthy volunteers.

Mark Egerton, PhD, CEO of Quotient Sciences, said: “We are delighted to be able to continue to assist Oxilio with their OXL001 program. By leveraging our unique, integrated Translational Pharmaceutics platform, Oxilio will have the flexibility to adjust doses based on emerging clinical data within their study, enabling us to improve their likelihood of success, reduce their development time, and ultimately get new medicines to patients faster.â€

Dr Simon Yaxley, Director of Oxilio, added: “Utilizing Quotient Sciences’ Translational Pharmaceutics platform has enabled us to successfully achieve this important milestone of receiving regulatory approval to undertake our first Phase 1 clinical trial with OXL001.  We look forward to commencing this study within the next few weeks.â€

 

Latest stories

Related stories

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharmâ€), a leading European specialty pharmaceutical company...

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Haleon today announces the appointment of Carl Haney as...

API China 2025 Concludes with Strong Turnout and Industry-Wide Momentum

Asia’s leading pharma show draws 200,000 visits and nearly...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back